Recent studies have demonstrated high expression of FoxI3 in bone metastases from prostate and breast cancers, suggesting that FoxI3 may promote bone metastasis and tumor growth and infiltration in the bone (Haider et al., 2016; Mukherjee et al., 2018). Here, FOXI3 is linked to neoplasm.